MA28922B1 - Nouveaux derives de phenylaminopyrimidine en tant qu'inhibiteurs de bcr-abl kinase - Google Patents

Nouveaux derives de phenylaminopyrimidine en tant qu'inhibiteurs de bcr-abl kinase

Info

Publication number
MA28922B1
MA28922B1 MA29808A MA29808A MA28922B1 MA 28922 B1 MA28922 B1 MA 28922B1 MA 29808 A MA29808 A MA 29808A MA 29808 A MA29808 A MA 29808A MA 28922 B1 MA28922 B1 MA 28922B1
Authority
MA
Morocco
Prior art keywords
bcr
kinase inhibitors
abl kinase
phenylaminopyrimidine derivatives
novel phenylaminopyrimidine
Prior art date
Application number
MA29808A
Other languages
English (en)
Inventor
Amala Kishan Kompella
Kali Satya Bhujanga Rao Adibhatla
Sreenivas Rachakonda
Khadgapathi Podili
Chowdary Nannapaneni Venkaiah
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MA28922B1 publication Critical patent/MA28922B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA29808A 2004-09-09 2007-04-06 Nouveaux derives de phenylaminopyrimidine en tant qu'inhibiteurs de bcr-abl kinase MA28922B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN908CH2004 2004-09-09

Publications (1)

Publication Number Publication Date
MA28922B1 true MA28922B1 (fr) 2007-10-01

Family

ID=35395645

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29808A MA28922B1 (fr) 2004-09-09 2007-04-06 Nouveaux derives de phenylaminopyrimidine en tant qu'inhibiteurs de bcr-abl kinase

Country Status (26)

Country Link
US (2) US7910598B2 (fr)
EP (2) EP2295424B1 (fr)
JP (1) JP5184887B2 (fr)
KR (1) KR100948453B1 (fr)
CN (1) CN101068805B (fr)
AP (1) AP2470A (fr)
AU (1) AU2005281299B2 (fr)
BR (1) BRPI0515081B8 (fr)
CA (1) CA2591321C (fr)
CY (1) CY1113617T1 (fr)
DK (1) DK1786799T3 (fr)
EA (1) EA013328B1 (fr)
ES (1) ES2390227T3 (fr)
HK (1) HK1110588A1 (fr)
HR (1) HRP20070146B1 (fr)
IL (1) IL181811A (fr)
MA (1) MA28922B1 (fr)
MX (1) MX2007002819A (fr)
NO (1) NO337598B1 (fr)
NZ (1) NZ554361A (fr)
PL (1) PL1786799T3 (fr)
PT (1) PT1786799E (fr)
SI (1) SI1786799T1 (fr)
UA (1) UA94570C2 (fr)
WO (1) WO2006027795A1 (fr)
ZA (2) ZA200701942B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CN101031569B (zh) 2004-05-13 2011-06-22 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
CN101068805B (zh) 2004-09-09 2013-04-03 纳科法尔马有限公司 作为bcr-abl激酶抑制剂的新的苯基氨基嘧啶衍生物
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US20110190328A1 (en) * 2004-09-09 2011-08-04 Natco Pharma Limited Acid addition salts of (3,5-bis trifluoromethyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US7939541B2 (en) 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
EP2069287A1 (fr) * 2006-09-11 2009-06-17 Syngeta Participations AG Composés insecticides
KR20120049397A (ko) * 2006-11-03 2012-05-16 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
EP2121608B1 (fr) * 2006-12-14 2012-11-14 Bayer Intellectual Property GmbH Dérivés de dihydropyridine utiles en tant qu'inhibiteurs de la protéine kinase
CN101720322A (zh) 2007-05-04 2010-06-02 Irm责任有限公司 作为c-kit和pdgfr激酶抑制剂的化合物和组合物
BRPI0811617A2 (pt) * 2007-05-04 2017-06-06 Irm Llc derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.
MX2010002004A (es) 2007-08-22 2010-03-11 Irm Llc Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa.
BRPI0815572A2 (pt) 2007-08-22 2015-02-18 Irm Llc Compostos e composições como inibidores de quinases
MX2010009401A (es) * 2008-03-04 2010-09-24 Natco Pharma Ltd Forma cristalina de derivado de fenilamino pirimidina.
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2012004801A1 (fr) * 2010-07-07 2012-01-12 Hetero Research Foundation Procédé de préparation de mésylate d'imatinib
GB2488788B (en) 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
MX339937B (es) 2011-09-01 2016-06-17 Novartis Ag * Compuestos y composiciones como inhibidores de la quinasa c-kit.
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
CA2876539A1 (fr) * 2012-06-15 2013-12-19 Basf Se Cristaux a plusieurs composants comprenant du dasatinib et des agents de formation de cocristaux choisis
UA122592C2 (uk) 2015-12-18 2020-12-10 Натко Фарма Лтд Фармацевтичні композиції, які містять похідні феніламінопіримідину
WO2017156350A1 (fr) 2016-03-09 2017-09-14 K-Gen, Inc. Méthodes de traitement du cancer
US11767319B2 (en) 2020-07-15 2023-09-26 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
EP4247368A1 (fr) 2020-11-19 2023-09-27 Third Harmonic Bio, Inc. Compositions pharmaceutiques d'un inhibiteur sélectif de la kinase c-kit et leurs procédés de fabrication et d'utilisation
CN113125689B (zh) * 2021-03-29 2022-02-22 创芯国际生物科技(广州)有限公司 一种新型mtt细胞活力检测试剂盒及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1995009851A1 (fr) 1993-10-01 1995-04-13 Ciba-Geigy Ag Derives de pyrimidineamine pharmacologiquement actifs ainsi que leurs procedes de preparation
DK0672041T3 (da) 1993-10-01 2002-02-25 Novartis Ag Farmakologisk aktive pyridinderivater og fremgangsmåder til fremstilling deraf
AU693475B2 (en) 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
KR20010024175A (ko) * 1997-09-23 2001-03-26 돈 리사 로얄 시토킨에 의해 매개되는 질환 치료용 아미드 유도체
IL141183A0 (en) * 1998-08-04 2002-02-10 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
RU2315043C2 (ru) * 2002-06-28 2008-01-20 Ниппон Синяку Ко., Лтд. Амидное производное, фармацевтическая композиция и терапевтические средства на его основе
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
WO2004108699A1 (fr) * 2003-06-06 2004-12-16 Natco Pharma Limited Nouveau procede de preparation du medicament anticancereux imatinibe et de nouveaux analogues de ce medicament
AU2004246800B2 (en) * 2003-06-13 2008-12-04 Novartis Ag 2-aminopyrimidine derivatives as Raf kinase inhibitors
CN101068805B (zh) 2004-09-09 2013-04-03 纳科法尔马有限公司 作为bcr-abl激酶抑制剂的新的苯基氨基嘧啶衍生物
KR20120049397A (ko) * 2006-11-03 2012-05-16 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물

Also Published As

Publication number Publication date
NO337598B1 (no) 2016-05-09
SI1786799T1 (sl) 2012-12-31
KR100948453B1 (ko) 2010-03-17
BRPI0515081B8 (pt) 2021-05-25
AU2005281299B2 (en) 2012-03-15
US20080306100A1 (en) 2008-12-11
ZA200701942B (en) 2008-10-29
CA2591321C (fr) 2013-09-24
US20070232633A1 (en) 2007-10-04
MX2007002819A (es) 2007-08-14
US7910598B2 (en) 2011-03-22
HRP20070146A2 (en) 2007-08-31
CA2591321A1 (fr) 2006-03-16
EP1786799A1 (fr) 2007-05-23
AP2470A (en) 2012-09-17
EA200700601A1 (ru) 2008-02-28
NZ554361A (en) 2009-03-31
ES2390227T3 (es) 2012-11-07
JP2008512448A (ja) 2008-04-24
EA013328B1 (ru) 2010-04-30
HRP20070146B1 (hr) 2015-12-04
BRPI0515081B1 (pt) 2021-05-04
DK1786799T3 (da) 2012-10-01
PL1786799T3 (pl) 2012-12-31
EP1786799B1 (fr) 2012-07-04
KR20070106681A (ko) 2007-11-05
PT1786799E (pt) 2012-09-18
CN101068805A (zh) 2007-11-07
CY1113617T1 (el) 2016-06-22
JP5184887B2 (ja) 2013-04-17
EP2295424A1 (fr) 2011-03-16
BRPI0515081A (pt) 2008-07-08
IL181811A0 (en) 2007-07-04
CN101068805B (zh) 2013-04-03
AP2007003944A0 (en) 2007-04-30
ZA200703123B (en) 2008-10-29
UA94570C2 (en) 2011-05-25
HK1110588A1 (en) 2008-07-18
US8183253B2 (en) 2012-05-22
WO2006027795A1 (fr) 2006-03-16
IL181811A (en) 2013-07-31
NO20071521L (no) 2007-06-11
EP2295424B1 (fr) 2015-10-14
AU2005281299A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
MA28922B1 (fr) Nouveaux derives de phenylaminopyrimidine en tant qu'inhibiteurs de bcr-abl kinase
FR22C1060I2 (fr) Imidazotriazines et imidazopyrimidines utilisees en tant qu'inhibiteurs de kinases
CY2015016I2 (el) Αναστολεις της κινασης τυροσινης του bruton
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602007014374D1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
FR20C1027I2 (fr) Derives de tiglien-3-one
MA28816B1 (fr) Nouveaux derives de 4-benzylidene-piperidine
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
MA29119B1 (fr) Derives de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
MA28824B1 (fr) Derives de pyrimidine
SMP200700051B (it) Imidazochinoline come inibitori di lipide chinasi
DK1881976T3 (da) Substituerede amidderivater som proteinkinaseinhibitorer
ATE524474T1 (de) Aminderivate mit tyrosinkinase hemmender wirkung
MA28813B1 (fr) Derives de pyrimidine
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
ATE413389T1 (de) Chinazolinderivate
DE602004004553D1 (de) Chinazolinderivate
MA28370A1 (fr) Derives de alkylpiperazine-et alkylhomopiperazine-carboxylates, leur preparation et leur application en tant qu'inhibiteurs de l'enzyme faah
DE602005007181D1 (de) 1h-thieno 2,3-c-pyrazol-derivate als kinase-i-hemmer
ATE449080T1 (de) 4-phenyl-6-substituierte pyrimidin-2- carbonitrilderivate
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
ATE417844T1 (de) Anthranilamid-derivate als insektizide
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
ATE521603T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
FR2878850B1 (fr) Derives de l'inositol-1-phosphate